View Older Stories View More Recent Stories

Apr 16, 2018 05:52AM Merck (MRK) Reports Results from Phase 3 EORTC1325/KEYNOTE-054 Trial Investigating KEYTRUDA as Adjuvant Therapy
Apr 15, 2018 04:50PM Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR
Apr 15, 2018 09:30AM Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent Compared to Placebo as Adjuvant Therapy in Resected, High-Risk Stage III Melanoma
Apr 9, 2018 06:45AM Merck (MRK) Says KEYTRUDA Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study
Apr 9, 2018 06:45AM KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing P
Apr 6, 2018 07:32AM Incyte (INCY) Phase 3 ECHO-301 Study Didn't Meet Primary Endpoint
Apr 6, 2018 07:30AM Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma
Apr 3, 2018 06:02AM Merck (MRK) Reports EMA Acceptance of Regulatory Submission for LYNPARZA (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer
Apr 3, 2018 06:00AM The European Medicines Agency Accepts Regulatory Submission for LYNPARZA® (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer
Apr 2, 2018 06:45AM Merck to Hold First-Quarter 2018 Sales and Earnings Conference Call on May 1
Mar 23, 2018 06:25AM Eisai, Merck (MRK) Announce Anticancer Agent LENVIMA was Approved for Additional Indication of HCC in Japan
Mar 23, 2018 06:00AM Anticancer Agent LENVIMA® (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC
Mar 21, 2018 06:24AM Merck's (MRK) MSD Animal Health Receives Positive Opinion from EMA for BRAVECTO Plus Spot-on Solution for Cats
Mar 21, 2018 02:00AM MSD Animal Health Receives Positive Opinion from European Medicines Agency for BRAVECTO® Plus (fluralaner plus moxidectin) Spot-on Solution for Cats
Mar 20, 2018 04:05PM Merck Announces Appointment of Jennifer Zachary as General Counsel
Mar 14, 2018 06:30PM First-Line Lung Cancer Data and Other New Research from Merck’s Broad Oncology Program to be Presented at AACR Annual Meeting
Mar 13, 2018 07:02AM Merck (MRK) Says FDA Granted Priority Review to its sBLA for KEYTRUDA for Treatment of Advanced Cervical Cancer
Mar 13, 2018 07:00AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Advanced Cervical Cancer
Mar 7, 2018 05:08PM Merck (MRK), Eisai Co. Enter Strategic Oncology Collaboration for LENVIMA
Mar 7, 2018 05:05PM Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate)
Mar 1, 2018 07:10AM Merck (MRK) to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI
Mar 1, 2018 07:00AM Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018
Feb 23, 2018 07:30AM Merck (MRK) Announces LYNPARZA Received Positive EU CHMP Opinion in Platinum-Sensitive Relapsed Ovarian Cancer
Feb 23, 2018 07:30AM LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion in Platinum-Sensitive Relapsed Ovarian Cancer
Feb 21, 2018 06:13AM Merck (MRK) to Acquire Viralytics for $394 Million
Feb 21, 2018 04:00AM Merck and Viralytics Announce Acquisition Agreement, Expanding Merck’s Leading Immuno-Oncology Pipeline
Feb 15, 2018 08:45AM Merck KGaA, Pfizer (PFE) Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced NSCLC
Feb 15, 2018 08:30AM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Feb 15, 2018 06:31AM AstraZeneca (AZN), Merck (MRK) Report Orphan Drug Designation by U.S. FDA for Neurofibromatosis Type 1
Feb 15, 2018 06:30AM Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Neurofibromatosis Type 1
Feb 13, 2018 04:34PM Merck (MRK) Ends APECS Study Evaluating Verubecestat (MK-8931) for Treatment of People with Prodromal Alzheimer's Disease
Feb 13, 2018 04:30PM Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer’s Disease
Feb 6, 2018 05:30PM First-of-its-Kind Study Reveals Concern about the Future of the Veterinary Profession
Feb 2, 2018 06:45AM Merck Announces Fourth-Quarter and Full-Year 2017 Financial Results
Jan 31, 2018 07:00AM Pro Football Hall of Famer and Cancer Survivor Jim Kelly Joins Merck to Challenge America to Raise Funds for the Cancer Community
Jan 24, 2018 07:00AM Inge Thulin Elected to Merck Board of Directors
Jan 23, 2018 02:47PM Merck Announces Second-Quarter 2018 Dividend
Jan 19, 2018 06:46AM Merck (MRK) Says First-Time Data for its KEYTRUDA in Patients with Previously Treated Advanced HCC to be Presented at ASCO GI Symposium
Jan 19, 2018 06:45AM First-Time Data for Merck’s KEYTRUDA® (pembrolizumab) in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) to be Presented at 2018 ASCO GI Symposium
Jan 19, 2018 06:37AM Merck (MRK) and AstraZeneca (AZN) Granted Approval for LYNPARZA (Olaparib) in Japan
Jan 19, 2018 06:30AM LYNPARZA® (olaparib) Receives Approval in Japan for the Treatment of Advanced Ovarian Cancer
Jan 16, 2018 06:46AM Merck's (MRK) KEYTRUDA Significantly Improved OS and PFS as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Patients with Metastatic NSCLC
Jan 16, 2018 06:45AM Merck's KEYTRUDA(R) (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Pati
Jan 12, 2018 12:46PM AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA Was Approved by US FDA in Germline BRCA-Mutated Metastatic Breast Cancer
Jan 12, 2018 12:45PM U.S. FDA Approves LYNPARZA® (olaparib) in Germline BRCA-Mutated Metastatic Breast Cancer
Jan 9, 2018 06:47AM Merck (MRK) and Eisai Secure Breakthrough Therapy Designation from FDA for LENVIMA (lenvatinib mesylate) & KEYTRUDA (pembrolizumab) as Combination Therapy for Advanced RCC
Jan 9, 2018 06:45AM Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell Ca
Jan 8, 2018 06:46AM Merck's (MRK) KEYTRUDA Significantly Improved RFS Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054)
Jan 8, 2018 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054
Jan 8, 2018 06:31AM Merck (MRK) Says FDA Accepted NDA for its Doravirine for Treatment of HIV-1 Infection
View More Recent Stories View Older Stories